fullness" will be presented by Nico Pannacciulli, MD, PhD, Sunday,
October 5 at 5:30 p.m. PT (8:30 p.m. ET).
7. Poster 489-P: "Central activation and weight-lowering actions of
AC164209, a peptide hybrid linking a glucagon-like peptide-1 (GLP-1)
receptor agonist and an amylin mimetic" will be presented by Christine
Mack, PhD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).
8. Corporate-sponsored symposium: "Emerging Peptide Hormone Therapies for
the Treatment of Obesity: Mechanisms of Action, Clinical Safety and
Efficacy." This medical educational symposium will help healthcare
providers understand the peptide hormone approach to the treatment of
obesity. The event will be chaired by George A. Bray, MD, MACP,
Saturday, October 4 at 7:15 p.m. PT (10:15 p.m. ET). This symposium
is supported by an unrestricted educational grant from Amylin
9. Corporate-sponsored symposium: "Reducing CVD Risk: Emerging Science
and Therapeutic Options in the Management of Obesity and Type 2
Diabetes." This medical education symposium will help healthcare
providers understand new science and therapeutic options to reducing
cardiovascular disease risk in the treatment of obesity and type 2
diabetes. The event will be chaired by Robert H. Eckel, MD, Monday,
October 6 at 5:45 p.m. PT (8:45 p.m. ET). This symposium is supported
by an unrestricted educational grant from Amylin Pharmaceuticals and
Eli Lilly and Company.
A full list of all Amylin abstracts being presented at the 2008 Obesity Society meeting is available at: http://www.obesity.org/annualmeeting08/OS_Phoenix08_Final_Program.pdf .
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved